Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > ARCHIVE
ARCHIVE
- WORLD NEWS IN BRIEF
February 5, 2001
- Korosho Holds 1st Explanatory Meeting for Prefectural Governmental Officials -2-
February 5, 2001
- JPA Holds National Convention to Prevent Dispensing Errors
February 5, 2001
- DIAGNOSTIC NEWS IN BRIEF
February 5, 2001
- BUSINESS NEWS IN BRIEF
February 5, 2001
- Cost Curtailment Policy Should Now Target Hospitalization: JHEF Seminar
February 5, 2001
- Takara Obtains Marketing Rights for Analysis Services from GeneFormatics
February 5, 2001
- ON THE MOVE
February 5, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 5, 2001
- CORPORATE ROUNDUP NEWS IN BRIEF
February 5, 2001
- Kirin Obtains Rights to Cerus's Allogeneic Cellular Immune Therapy Technology
February 5, 2001
- NHI Prices of 12 New Ingredients Including Tamiflu, Relenza Approved
February 5, 2001
- Kissei, Teikoku Hormone to Codevelop Threatened Premature Delivery Treatment
February 5, 2001
- Peak Sales of 5 New Drugs Expected to Exceed \10 Bil.: Chuikyo
February 5, 2001
- Proposed Human Genome Research GL Explained by Kyoto Univ. Professor
February 5, 2001
- Chuikyo Members Point Out Problems with NHI Price Setting Rules
February 5, 2001
- Foundation for Biomedical Research and Innovation Ties Up with Quintiles
February 5, 2001
- Overall Mortality Increases at Total Cholesterol of 180 mg/dl or Less
January 29, 2001
- Santen Agrees with Nippon Organon to Develop, Manufacture, Market Glaucoma Treatment
January 29, 2001
- Novartis 5-Generation Campaign Recruits 378 Families
January 29, 2001
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…